Anderson GL et al; Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. JAMA 2004;291(14):1701-12. Abstract

Bajetta E et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23(10):2155-61. Abstract

Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 2005;89(Suppl 1):9-15. Abstract

Hess D et al. Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: A phase I trial (SAKK 25/99). Ann Oncol 2004;15(12):1760-5. Abstract

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Keen JC et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2’-deoxycytidine. Breast Cancer Res Treat 2003;81(3):177-86. Abstract

O’Shaughnessy J et al. ABI-007 (ABRAXANE), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs taxol in MBC: A phase III trial. San Antonio Breast Cancer Symposium 2003;Abstract 44.

O’Shaughnessy JA et al. Weekly nanoparticle albumin paclitaxel (Abraxane) results in longterm disease control in patients with taxane-refractory metastatic breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 1070.

Rossouw JE et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288(3):321-33. Abstract

Thürlimann B et al. Letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: A prospective randomized double-blind Phase III study. Breast 2005a;14(Suppl 1):3;S4.

Thürlimann BJ et al. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptorpositive breast cancer. Presentation. ASCO 2005b;Abstract 511.

Zamora P et al. Capecitabine (X) as single agent in elderly patients (p) with metastatic breast cancer (MBC). Proc ASCO 2005;Abstract 843.